What Royal Jelly Is
Royal jelly is a glandular secretion produced by young worker bees (nurse bees) and fed to all larvae for the first few days of life — but the future queen continues receiving it exclusively throughout development. This dietary difference alone accounts for the dramatic divergence in lifespan, body size, reproductive capacity, and behavior between a queen and a worker bee.
The composition of fresh royal jelly is roughly 67% water, 12% protein, 11% simple sugars, 6% fatty acids, and small amounts of vitamins, minerals, and acetylcholine. The proteins include a family called major royal jelly proteins (MRJPs), particularly royalactin, which triggers the physiological changes in queen development.
The defining bioactive compound, however, is 10-HDA — a medium-chain hydroxy fatty acid that constitutes 1.4–2% of fresh royal jelly by weight. No other food or organism produces it.
Neuroprotection and Cognitive Function
The most compelling emerging research on royal jelly concerns the brain. 10-HDA and the MRJP family appear to support neurogenesis (growth of new neurons) and protect existing neural tissue from oxidative stress and inflammation.
Animal models have shown that oral royal jelly supplementation leads to measurable improvements in memory and spatial learning. In a 2020 study using a rat model of sporadic Alzheimer's disease — induced by intracerebroventricular injection of streptozotocin — royal jelly treatment significantly improved memory performance compared to untreated animals, and post-mortem analysis showed reduced neurodegeneration markers in the hippocampus [2]. This suggests a neuroprotective effect beyond simple stimulation.
In humans, a 2024 randomized controlled trial found that ischemic stroke patients receiving royal jelly supplementation had meaningfully better recovery outcomes compared to placebo, including improvements in cognitive function and reduced inflammatory markers post-stroke [3]. This is preliminary but notable for a food-based intervention.
Menopausal Support
Two randomized controlled trials have found royal jelly to be beneficial for perimenopausal and postmenopausal women. A 2019 Iranian RCT found that 1,000 mg daily of royal jelly significantly reduced overall menopausal symptom scores on the Menopause Rating Scale compared to placebo, with effects on hot flashes, sleep disturbance, and mood [4].
A 2018 Japanese RCT (n=61) found that royal jelly supplementation specifically improved backache, low back pain, and anxiety in postmenopausal women [5]. The proposed mechanism involves the estrogenic-like activity of 10-HDA, which can bind weakly to estrogen receptors without the risks associated with exogenous estrogen. This may make royal jelly a relevant option for women seeking non-hormonal support for menopause symptoms.
See also our black cohosh page and red clover page for other evidence-based non-hormonal menopause options.
Skin and Collagen
Royal jelly has a long history in cosmetics, and there is mechanistic data to support it. A 2011 cell study found that royal jelly protected human skin fibroblasts from UV-B-induced damage — a primary driver of photoaging — and significantly increased procollagen type I synthesis [6]. Collagen is the structural protein that gives skin its firmness and elasticity, and UV exposure accelerates its degradation.
The effect was attributed to 10-HDA and the MRJP proteins, which appeared to stimulate fibroblast activity and counteract UV-induced oxidative stress. While cell studies don't directly translate to clinical outcomes, they establish a plausible mechanism for the traditional use of royal jelly in skin care.
Lipid Profile and Cardiovascular Markers
A 2017 double-blind RCT in mildly hypercholesterolemic adults found that 10 weeks of royal jelly supplementation (3,000 mg/day) significantly reduced total cholesterol and LDL-cholesterol compared to placebo [7]. The effect size was modest — a reduction of approximately 14% in LDL — but consistent with its historically proposed role as a cardiovascular tonic in traditional Japanese medicine (where it has been consumed as a supplement for decades).
How to Use Royal Jelly
Royal jelly is available in several forms:
- Fresh royal jelly: The most potent form, typically stored frozen or refrigerated. Taken sublingually or swallowed directly. Typical doses in research range from 300 mg to 3,000 mg per day.
- Freeze-dried capsules or powder: More stable and convenient, though some bioactive compounds may be reduced compared to fresh.
- Blended with honey: A traditional preparation that extends shelf life and palatability.
Fresh royal jelly has a distinctly acidic, slightly bitter taste. It should be refrigerated and consumed within 6–12 months of production. Look for suppliers who store at sub-zero temperatures before shipping.
Precautions: Royal jelly can cause allergic reactions, occasionally severe, in people with bee allergies or atopic conditions. Asthmatics in particular should start with small amounts. There are rare case reports of anaphylaxis. It is not recommended during pregnancy due to its estrogenic activity and lack of safety data.
Evidence Review
Anti-inflammatory and Antimicrobial Mechanisms of 10-HDA
Yang et al. (2018) examined the bactericidal and anti-inflammatory activity of 10-HDA in human colon cancer cell cultures (HCT-116 cells). They found that 10-HDA inhibited LPS-induced production of pro-inflammatory cytokines including IL-6, IL-8, and TNF-α, and demonstrated direct antimicrobial activity against several bacterial strains [1]. The study establishes 10-HDA as the primary bioactive driver of royal jelly's anti-inflammatory effects and explains mechanistically why royal jelly may reduce inflammatory biomarkers in clinical studies.
Limitations: This was an in vitro study; cell-based findings require confirmation in human trials before clinical conclusions can be drawn.
Neuroprotection in Alzheimer's Animal Model
Guardia de Souza E Silva et al. (2020) treated rats with intracerebroventricular streptozotocin (ICV-STZ), a validated model of sporadic Alzheimer's disease, with or without oral royal jelly supplementation. The royal-jelly group showed significantly better performance on the Morris water maze (spatial memory) and object recognition tests. Post-mortem analysis revealed reduced tau hyperphosphorylation and amyloid-related markers in the hippocampus, alongside higher antioxidant enzyme activity [2]. Sample size was n=32 animals across four groups. Duration: 30 days.
Limitations: Animal models, even validated ones, do not reliably predict human therapeutic response. No human RCTs on Alzheimer's prevention exist yet for royal jelly.
Post-Stroke Cognitive Recovery RCT
Karimi et al. (2024) conducted a randomized, placebo-controlled trial in 60 ischemic stroke patients. The intervention group received royal jelly supplementation (1,000 mg/day) for 8 weeks. Outcomes measured included cognitive function (Montreal Cognitive Assessment), inflammatory biomarkers (hs-CRP, IL-6), and oxidative stress markers (MDA, TAC). The royal jelly group showed significantly greater improvement in cognitive scores and significantly lower inflammatory and oxidative stress markers compared to placebo [3]. This is the highest-quality human evidence for royal jelly's neurological effects to date.
Limitations: Single-center study with 30 patients per arm; short 8-week duration. Stroke recovery involves complex processes, and the mechanisms driving the benefit are not fully understood.
Menopausal Symptoms: Two RCTs
Sharif and Darsareh (2019) randomized 200 perimenopausal and postmenopausal women in Iran to 1,000 mg royal jelly daily or placebo for 8 weeks. Menopause symptom severity was assessed by the Menopause Rating Scale. Royal jelly significantly reduced total symptom scores compared to placebo (p < 0.001), with improvements across somatic, psychological, and urogenital subscales [4].
Asama et al. (2018) conducted a smaller RCT (n=61 postmenopausal Japanese women) over 12 weeks using 800 mg/day of royal jelly. They found significant improvements specifically in back and low back pain, anxiety, and overall quality of life in the active group versus placebo [5]. The proposed mechanism involves 10-HDA's weak estrogenic receptor activity, which may compensate partially for declining endogenous estrogen without the risks of hormone replacement therapy.
Strength of evidence: Two concordant RCTs in different populations is a meaningful signal. However, both trials were relatively short and neither measured hormonal biomarkers directly.
Skin Collagen and UV Protection
Park et al. (2011) exposed human dermal fibroblasts to UV-B radiation with and without royal jelly extract pretreatment. Royal jelly significantly attenuated UV-B-induced cell death, reduced ROS (reactive oxygen species) production, and — critically — increased type I procollagen synthesis in a dose-dependent manner [6]. The effect was attributed primarily to the protein fraction (MRJPs) rather than 10-HDA alone.
Limitation: In vitro only. Topical or oral application studies in humans with quantitative collagen outcomes have not yet been published in peer-reviewed literature.
Cholesterol Reduction RCT
Chiu et al. (2017) enrolled 40 mildly hypercholesterolemic adults (total cholesterol 200–240 mg/dL) in a double-blind, placebo-controlled crossover trial. Ten weeks of 3,000 mg/day royal jelly capsules reduced total cholesterol by approximately 11%, LDL by approximately 14%, and triglycerides by approximately 6% compared to baseline, with no changes in the placebo group [7]. HDL was not significantly affected.
Strength of evidence: Rigorous crossover design controls for individual variability. The dose used (3,000 mg/day) is at the higher end of typical supplementation. Effect sizes are modest but consistent with other dietary interventions for lipid management.
Overall Assessment
Royal jelly has a moderate and growing evidence base. The menopausal RCTs and the cholesterol RCT are well-designed and provide reliable clinical signals. The neuroprotection evidence is strong in animal models with one human RCT supporting the direction of effect. The anti-inflammatory and skin data are mechanistic (in vitro) and support biological plausibility rather than clinical recommendations. Evidence quality is generally moderate — better than many traditional remedies but not yet at the level of pharmaceutical-grade certainty. For women seeking non-hormonal menopausal support in particular, the evidence is reasonably strong for modest symptomatic benefit.